Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tripelennamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.97 |
| ▸ | LMNA | P02545 | 4/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tripelennamine SCHEMBL29600775 | 1.00 | CHRM2 (1.00) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Tripelennamine SCHEMBL98916 | 0.98 | KDM4E (1.00) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Tripelennamine SCHEMBL29363256 | 0.98 | KDM4E (1.00) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Tripelennamine SCHEMBL1652325 | 0.98 | CHRM2 (0.97) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Tripelennamine SCHEMBL15270438 | 0.94 | CHRM2 (0.89) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Chloropyramine SCHEMBL13723581 | 0.92 | CYP2D6 (0.95) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Tripelennamine SCHEMBL5432608 | 0.90 | CHRM2 (0.82) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| SCHEMBL16491454 | 0.89 | CHRM2 (0.81) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Pyrilamine SCHEMBL622845 | 0.89 | LMNA (0.95) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 | |
| Chloropyramine SCHEMBL30021 | 0.88 | CYP2D6 (1.00) | CHRM2ADRA2ADRD1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12608 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260027008-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP TECHNOLOGIES, INC. | 2026-01-29 | — | — | US | claimed |
| WO-2025264260-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP TECHNOLOGIES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| EP-4630446-A1 | ENGINEERED SWITCHES FOR IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF | Dynamic Cell Therapies, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4630401-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | Rutgers, the State University of New Jersey (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4630043-A1 | IMMUNE-ACTIVATING COMPLEXES | Dynamic Cell Therapies, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4247331-B1 | ORODISPERSIBLE POWDER COMPOSITION COMPRISING AN ANTIHISTAMINE COMPOUND | BIOPHARMA SYNERGIES S L (ES) | 2025-10-08 | — | — | EP | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| EP-0073971-B1 | THIADIAZOLE OXIDES AS GASTRIC ANTISECRETORY AGENTS | MERCK & CO. INC. (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0180597-A1 | COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS. | SUNSHINE ABRAHAM (US) | 1986-05-14 | — | — | EP | claimed |
| WO-1986002553-A1 | NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME | NASTECH PHARMACEUTICAL COMPANY, INC. (US) | 1986-05-09 | — | — | WO | claimed |
| WO-1985004589-A1 | COUGH/COLD MIXTURES COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | SUNSHINE ABRAHAM | 1985-10-24 | — | — | WO | claimed |
| US-4411899-A | Substituted derivatives of amino alkane diols as gastric secretion inhibitors | MERCK & CO., INC. (US) | 1983-10-25 | — | — | US | claimed |
| EP-0082376-A2 | Substituted derivatives of amino alkane diols as gastric secretion inhibitors | MERCK & CO. INC. (US) | 1983-06-29 | — | — | EP | claimed |
| EP-0073971-A1 | Thiadiazole oxides as gastric antisecretory agents | MERCK & CO. INC. (US) | 1983-03-16 | — | — | EP | claimed |
| US-4234566-A | Antihistamine and methods for use thereof | CARTER-WALLACE, INC. | 1980-11-18 | — | — | US | claimed |
| US-4226850-A | ANTIHISTAMINES | CARTER-WALLACE, INC., A CORP. OF DE | 1980-10-07 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |